Objectives

To summarize the role of Bruton tyrosine kinase (BTK) inhibitors in the management of chronic lymphocytic leukemia with a focus on the nursing role in relation to patients with chronic lymphocytic leukemia being treated with BTK inhibitors.

Data Sources

These include published articles (PubMed) and national and international guideline documents.

Conclusion

BTK inhibitors have revolutionized the therapy of chronic lymphocytic leukemia and have become the most frequently used therapy today. Despite the many advantages of BTK inhibitors, adverse events remain a leading cause of treatment discontinuation, particularly for the first-in-class BTK inhibitor. Second-generation BTK inhibitors appear to have a better tolerability profile but still require adverse event management given their prolonged duration of therapy. Awareness and management of side effects by the oncology care team is essential for ensuring both compliance and safety with ongoing treatment.

Implications for Nursing Practice

Chronic lymphocytic leukemia is a chronic illness with a long-life expectancy. For the patients who require therapy, BTK inhibitor therapy is a frequently applied treatment with impressive efficacy. BTK inhibitors are continued indefinitely until disease progression or significant toxicity; therefore, the overall principles of careful assessment for side effects, diligent management for these, and individualized patient support provided by oncology nurses is vital in this patient population.

中文翻译：

---

用布鲁顿酪氨酸激酶抑制剂治疗 CLL：门诊肿瘤科护士的作用

目标

总结布鲁顿酪氨酸激酶 (BTK) 抑制剂在慢性淋巴细胞白血病治疗中的作用，重点是对接受 BTK 抑制剂治疗的慢性淋巴细胞白血病患者的护理作用。

数据源

这些包括已发表的文章 (PubMed) 以及国家和国际指南文件。

结论

BTK 抑制剂彻底改变了慢性淋巴细胞白血病的治疗方法，并成为当今最常用的治疗方法。尽管 BTK 抑制剂有许多优点，但不良事件仍然是停止治疗的主要原因，特别是对于一流的 BTK 抑制剂。第二代 BTK 抑制剂似乎具有更好的耐受性，但鉴于其治疗持续时间较长，仍需要不良事件管理。肿瘤护理团队对副作用的认识和管理对于确保持续治疗的依从性和安全性至关重要。

对护理实践的影响

慢性淋巴细胞白血病是一种预期寿命较长的慢性疾病。对于需要治疗的患者，BTK抑制剂治疗是一种常用的治疗方法，疗效显着。BTK 抑制剂无限期持续使用，直至疾病进展或出现显着毒性；因此，仔细评估副作用、认真管理这些副作用以及肿瘤科护士提供的个性化患者支持的总体原则对于该患者群体至关重要。